Know Cancer

forgot password

Effect of Aromatase Inhibitor Therapy for Breast Cancer on Endothelial Function

40 Years
80 Years
Open (Enrolling)
Breast Cancer

Thank you

Trial Information

Effect of Aromatase Inhibitor Therapy for Breast Cancer on Endothelial Function


- Determine the effect of adjuvant aromatase inhibitor therapy on endothelial function in
postmenopausal women with breast cancer.

OUTLINE: This is a multicenter study. Patients are assigned to 1 of 2 treatment groups
according to breast cancer hormone-receptor status (positive vs negative).

- Group 1 (hormone receptor-positive): Patients receive aromatase inhibition therapy for
up to 6 months in the absence of unacceptable toxicity.

- Group 2 (hormone receptor-negative): Patients do not receive adjuvant treatment.

Endothelial function is measured in both groups at baseline and at follow up by the room
temperature peripheral arterial tonometry (RT-PAT) index using the EndoPAT method.

Inclusion Criteria


- Diagnosis of breast cancer

- Ductal carcinoma in situ (DCIS) allowed provided the patient will not receive
tamoxifen as part of treatment for their cancer

- May not have had a prior mastectomy with requirement for mastectomy of the
contralateral breast

- No requirement for axillary lymph node dissection with a history of contralateral
mastectomy and/or contralateral axillary lymph node dissection

- Hormone receptor status meeting 1 of the following criteria:

- Hormone receptor negative and not eligible for aromatase inhibitor therapy (AI)

- Hormone receptor positive and are not receiving an AI


- Postmenopausal

- No known or symptomatic coronary artery disease

- No significant co-morbidities, including any of the following conditions:

- Active renal or hepatic disease

- Known uncontrolled and/or untreated peripheral arterial disease

- Uncontrolled and/or untreated hypertension

- Uncontrolled and/or untreated diabetes

- Uncontrolled and/or untreated hyperlipidemia


- See Disease Characteristics

- More than 7 days since prior hormone replacement therapy or hormone-based

- More than 12 months since prior and no concurrent tamoxifen or aromatase inhibitor
therapy for this disease

- More than 12 months since prior and no concurrent chemotherapy for this disease

- No prior bilateral mastectomy

Type of Study:


Study Design:

Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Endothelial dysfunction as a result of aromatase inhibitor therapy

Safety Issue:


Principal Investigator

Nicole P. Sandhu, M.D., Ph.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Mayo Clinic


United States: Federal Government

Study ID:




Start Date:

June 2008

Completion Date:

Related Keywords:

  • Breast Cancer
  • stage IA breast cancer
  • stage IB breast cancer
  • stage II breast cancer
  • stage IIIA breast cancer
  • stage IIIB breast cancer
  • stage IIIC breast cancer
  • stage IV breast cancer
  • ductal breast carcinoma in situ
  • Breast Neoplasms



Mayo Clinic Rochester, Minnesota  55905